Scarica l'app Stockscreener
41.40
2.27%
0.92
Dopo l'orario di chiusura:
41.40
Precedente Chiudi:
$40.48
Aprire:
$41.01
Volume 24 ore:
1.43M
Relative Volume:
1.15
Capitalizzazione di mercato:
$4.50B
Reddito:
-
Utile/perdita netta:
$-176.01M
Rapporto P/E:
-24.92
EPS:
-1.661
Flusso di cassa netto:
$-148.97M
1 W Prestazione:
+5.24%
1M Prestazione:
-1.38%
6M Prestazione:
+24.21%
1 anno Prestazione:
+176.00%
Intervallo 1D:
$40.42
$41.94
Intervallo di 1 settimana:
$38.51
$42.12
Portata 52W:
$14.25
$48.51
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
41.40 | 4.27B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Goldman | Neutral |
| 2025-07-30 | Iniziato | Raymond James | Strong Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
(EWTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - theglobeandmail.com
Edgewise Therapeutics Down Over 9%, on Pace for Largest Percent Decrease Since December 2025 -- Data Talk - Moomoo
Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says - marketscreener.com
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57 - moomoo.com
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500Slideshow (NASDAQ:EWTX) 2026-09-22 - Seeking Alpha
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic CardiomyopathySlideshow (NASDAQ:EWTX) 2026-06-17 - Seeking Alpha
EWTX: EDG-7500 improves cardiac relaxation in HCM and advances to Phase 3 after positive Phase 2 data - TradingView
Edgewise unveils mechanism of action for heart drug EDG-7500 By Investing.com - Investing.com Australia
Edgewise unveils mechanism of action for heart drug EDG-7500 - Investing.com
Edgewise Therapeutics unveils EDG-7500, a new d... - Pluang
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 - PR Newswire
EWTX Maintained by HC Wainwright & Co. -- Price Target Raised to $57.00 - GuruFocus
HC Wainwright & Co. maintains Buy rating on Edgewise Therapeutics, $57 price target - TradingView
Biotech Options Buzz: UTHR, NMRA, EWTX - Schaeffer's Investment Research
Edgewise Therapeutics stock hits all-time high at 48.41 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics stock hits all-time high at 48.41 USD - Investing.com
CIRRUS-HCM: EDG-7500 Improves LVOT, NYHA Class in oHCM and nHCM - HCPLive
Edgewise Therapeutics Jumps As EDG-7500 Data Fuels Bullish Target Hike - StocksToTrade
Edgewise Therapeutics Stock Jumps As JPMorgan Hikes Target - timothysykes.com
Edgewise Therapeutics Stock Rises as JPMorgan Lifts Price Target - timothysykes.com
Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Four new employees receive stock awards from Edgewise - Stock Titan
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59 - Moomoo
The Technical Signals Behind (EWTX) That Institutions Follow - Stock Traders Daily
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 - PR Newswire
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - Eastern Progress
Edgewise Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
EWTX Maintains Overweight Rating -- Price Target Raised to $60 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising SpendHas The Bull Case Changed? - simplywall.st
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Edgewise (EWTX) Results and Estimates: The Available Earnings Metric Delivers a Miss in the Available Record; Price Reaction: The Stock Ends Up 0.16% in Latest TradingConsensus Miss Rate - vinanet.vn
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics (EWTX) corrects CFO option grant price - Stock Titan
Edgewise Therapeutics (EWTX) corrects CMO’s 65K option grant price - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - MarketBeat
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - MarketBeat
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich - Sahm
Edgewise Therapeutics (EWTX) Gains 2.29% to $44.17, Maintains Upside MomentumStock Surge Alerts - vinanet.vn
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edgewise Therapeutics Inc Azioni (EWTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
Aug 12 '26 |
Sale |
43.85 |
6,522 |
286,000 |
11,544 |
| Donovan Joanne M. | CMO |
Aug 13 '26 |
Sale |
43.41 |
2,919 |
126,704 |
8,625 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
12,812 |
0 |
37,367 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Sale |
43.73 |
5,901 |
258,042 |
31,466 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Option Exercise |
0.00 |
12,499 |
0 |
22,713 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Sale |
43.82 |
5,016 |
219,823 |
17,697 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
13,281 |
0 |
36,926 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Sale |
43.81 |
5,100 |
223,424 |
31,826 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Option Exercise |
0.00 |
39,844 |
0 |
70,459 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Sale |
43.68 |
17,971 |
785,042 |
52,488 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):